Overview

• QuidelOrtho reports Q3 revenue of $700 mln, beating analysts' expectations

• Adjusted EPS beats consensus, reflecting effective cost-savings initiatives

• Company reports goodwill impairment charge of $701 mln, impacting GAAP net loss

Outlook

• QuidelOrtho sees full-year 2025 revenue between $2.68 bln and $2.74 bln

• Company expects full-year 2025 adjusted EBITDA of $585 mln to $605 mln

• QuidelOrtho forecasts full-year 2025 adjusted EPS between $2.00 and $2.15

Result Drivers

• REVENUE DECLINE - Total revenue decreased 4% due to lower COVID-19 and Donor Screening revenue

• COST-SAVINGS INITIATIVES - Decreased operating expenses and improved adjusted EBITDA margin attributed to cost-savings measures

• DEBT REFINANCING - Successful debt refinancing improved financial flexibility through better terms and reduced obligations

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for QuidelOrtho Corp is $34.00, about 20.2% above its November 4 closing price of $27.13

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nPn9KJl95a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)